Matthew Korenberg
2018
In 2018, Matthew Korenberg earned a total compensation of $2.7M as Executive Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $235,641 |
|---|---|
| Option Awards | $921,591 |
| Salary | $428,438 |
| Stock Awards | $1,077,560 |
| Other | $5,400 |
| Total | $2,668,630 |
Korenberg received $1.1M in stock awards, accounting for 40% of the total pay in 2018.
Korenberg also received $235.6K in non-equity incentive plan, $921.6K in option awards, $428.4K in salary and $5.4K in other compensation.
Rankings
In 2018, Matthew Korenberg's compensation ranked 4,381st out of 14,244 executives tracked by ExecPay. In other words, Korenberg earned more than 69.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,381 out of 14,244 | 69th |
Division Manufacturing | 1,632 out of 5,759 | 72nd |
Major group Chemicals And Allied Products | 587 out of 2,122 | 72nd |
Industry group Drugs | 491 out of 1,811 | 73rd |
Industry Pharmaceutical Preparations | 383 out of 1,385 | 72nd |
Source: SEC filing on April 24, 2020.
Korenberg's colleagues
We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2018.